Allergan and Gedeon Richter Plc. to Present Data from Cariprazine trials at European College of Neuropsychopharmacology (ECNP) Annual Meeting in Amsterdam

-- Presentations Include Cariprazine Data in Schizophrenia Patients with Predominant Negative Symptoms, Schizophrenia Relapse Prevention --

Aug 25, 2015, 02:00 ET from Allergan plc from ,Gedeon Richter

DUBLIN and BUDAPEST, Hungary, Aug. 25, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Gedeon Richter Plc today announced they will present data on the investigational drug cariprazine in patients with schizophrenia and acute mania in bipolar I disorder during the 28th European College of Neuropsychopharmacology (ECNP) annual congress in Amsterdam, to be held August 29September 1, 2015.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

Data presented include the first detailed results of cariprazine for the potential treatment of schizophrenia patients with predominant negative symptoms.

Richter Poster

Mon., August 31, 12:15-1:45 pm CEST

  • Cariprazine as Monotherapy for the Treatment of Schizophrenia Patients with Predominant Negative Symptoms: A Double-Blind, Active Controlled Trial (abstract #P.3.d.053), authored by Debelle, M., Nemeth, G., Szalai, E., Szatmari, B., Harsanyi, J., Barabassy, A., Laszlovszky, I.

Allergan and Richter Posters

Mon., August 31, 12:15-1:45 pm CEST

  • Long-Term Cariprazine Treatment for the Prevention of Relapse in Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Trial (abstract #P.3.d.057), authored by Durgam, S., Earley, W., Li, R., Li, D., Lu, K., Laszlovszky, I., Fleischhacker, W.W., Lieberman, J.A.
  • Categorical Improvement Across Mania Symptoms: Pooled Analyses of Cariprazine Phase II/III Trials (abstract #P.2.d.014), authored by Durgam, S., Laszlovszky, I., Lu, K., Ruth, A., Debelle, M., Zukin, S.

Tues., September 1, 12:15-1:45 pm CEST

  • Cariprazine Reduces Agitation and Hostility Associated With Schizophrenia (abstract #P.3.d.073), authored by Citrome, L., Lu, K., Ferguson, P., Laszlovszky, I., Earley, W., Durgam, S.

About Cariprazine

Cariprazine, an investigational drug, is an atypical antipsychotic being developed for the treatment of patients with schizophrenia and for patients with manic or mixed episodes associated with bipolar I disorder. The safety and efficacy of cariprazine was studied in a clinical trial program of more than 2,700 patients with these conditions. In addition, cariprazine is being investigated for the treatment of bipolar depression and adjunctive major depressive disorder (MDD) in adults. Cariprazine was discovered and co-developed by Gedeon Richter Plc and is licensed to Actavis, now Allergan, in the U.S. and Canada.

About Gedeon Richter

Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Richter's consolidated sales were approximately EUR 1.1 billion (US$ 1.5 billion), while its market capitalization amounted to EUR 2.1 billion (US$ 2.5 billion) in 2014. The product portfolio of Richter covers almost all important therapeutic areas, including gynaecology, central nervous system, and cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in biosimilar product development.

About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law,Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the risks associated with acquisition transactions; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 (such periodic public filings having been filed under the "Actavis plc" name) and from time to time in Allergan's other investor communications . Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

ALLERGAN CONTACTS:

Investors:  Lisa DeFrancesco  (862) 261-7152

Media:   Mark Marmur  (862) 261-7558

GEDEON RICHTER CONTACTS:

Investors:  Katalin Ordog +36 1 431 5680

Media: Zsuzsa Beke +36 1 431 4888

SOURCE Allergan plc; Gedeon Richter



RELATED LINKS

http://www.allergan.com


http://www.richter.hu